Suven Life Sciences Limited

Suven Life Science Limited

Jyothsna Ravula

Venkateswarlu Jasti

Ramakrishna Nirogi

Anil Karbhari Shinde

Pradeep Jayarajan

Sriramachandra Murthy Patnala

Abdul Rasheed Mohammed

Gopinadh Bhyrapuneni

Ishtiyaque Ahmad

Ramasastri Kambhampati

Srinivasa Rao Ravella

Suresh Yarlagadda

Praveen Kumar Roayapalley

Rama Sastri Kambhampati

Vijay Sidram Benade

Nagaraj Vishwottam Kandikere

Ramkumar Subramanian

Vinod Kumar Goyal

Santosh Kumar Pandey

Koteshwara Mudigonda

Saivishal Daripelli

Reddy Venkat Mekala

Dhanunjay Kumar Dogiparti

Ramkumar Subramaniam

Reddy Muddukrishna Chillakur

Ishtiyaque Ahmed

Satish Jetta

Raghava Chowdary Palacharla

The present invention relates to a pharmaceutical composition comprising solid dispersion of amorphous abiraterone acetate and one or more pharmaceutically acceptable excipients, having improved solubility, stability, bioavailability, and no positive food effect. The present invention also relates to a method for its preparation, a dosage form comprising such compositions, and the use of the said composition or dosage form as a medicament for the treatment of prostate cancer.

Amorphous pharmaceutical compositions of abiraterone acetate

The present invention provides new methods of treatment for narcolepsy, excessive daytime sleepiness, obstructive sleep apnea, circadian rhythm sleep disorders, sleep and vigilance disorders associated with Parkinson's disease, multiple sclerosis, dementia or attention deficit hyperactivity disorder by administering a therapeutically effect amount of histamine-3 receptor (H3R) inverse agonist, N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof. The present invention further provides use of the said compounds in the manufacture of medicament intended for the treatment of the disorders described herein.

Method of treatment with histamine-3 receptor inverse agonist

The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them.  The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HTreceptors.

[object Object]

The present invention relates to novel 1,2-dihydro-2-oxoquinoline compounds of the formula (I), and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them.  The present invention also relates to a process for the preparation of above said novel compounds, and their derivatives, prodrugs, tautomers, stereoisomers, polymorphs, solvates, hydrates, metabolites, N-oxides, pharmaceutically acceptable salts and compositions containing them. The compounds of the present invention are useful in the treatment/prevention of various disorders that are mediated by 5-HT4 receptor activity.

The present invention provides novel functional assay for 5-HT, histamine H1 or adrenergic alpha 1b receptors, by measuring intracellular cyclic adenosine monophosphate (cAMP) levels utilizing reporter gene driven cell based assay. The novel assay provides both binding affinity as well as mode of action of compounds in a single set. The novel assay of the invention is useful in identification of compounds acting through 5-HT, histamine H1 or adrenergic alpha 1b receptors. Furthermore, the assay offers utility in categorizing compounds in to agonist, partial agonist, inverse agonist and antagonist classes. The novel assay can be scaled up to any high throughput format.

Functional assay for 5-HT2A, histamine H1 or adrenergic alpha 1B receptors

Growing community of inventors

Hyderabad Telangana, India

Jyothsna Ravula